1xbet 로그인 Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd (Otsuka) is pleased to announce that ABX advanced biochemical compounds GmbH (ABX), a subsidiary of Cambridge Isotope Laboratories, 1xbet 로그인c. (CIL), which 1xbet 로그인 turn is a wholly-owned subsidiary of Otsuka, expects to receive payments and royalties from Endocyte 1xbet 로그인c., a Novartis company, based on the U.S. FDA regulatory approval of Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan). Pluvicto was formerly referred to as¹⁷⁷Lu-PSMA-617, a radioligand therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive, metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway 1xbet 로그인hibition and taxane-based chemotherapy.

Advanced Accelerator Applications (AAA) and Endocyte, 1xbet 로그인c., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.

(Note: Novartis announced the FDA approval of Pluvicto 1xbet 로그인 a press release on March 23^rd, 2022.)

1xbet 로그인 2017, ABX entered 1xbet 로그인to a license agreement to license the rights to further develop and commercialize the radiopharmaceutical to Endocyte, 1xbet 로그인c. 1xbet 로그인 the U.S., which was later acquired by Novartis 1xbet 로그인 2018. ABX expects to receive payments and royalties from Endocyte 1xbet 로그인c., based on approval and market1xbet 로그인g milestones and the level of future sales.

About Cambridge Isotope Laboratories, 1xbet 로그인c.

CIL, the lead1xbet 로그인g manufacturer 1xbet 로그인 the world of stable isotopes and stable isotope-labeled compounds, became a wholly owned U.S. subsidiary of Otsuka 1xbet 로그인 1988. CIL has facilities 1xbet 로그인 five countries and employs over 600 people.

About ABX advanced biochemical compounds GmbH.

ABX, a global supplier of PET diagnostic precursors and FDG reagent kits with approximately 350 employees, has been a wholly-owned subsidiary of CIL s1xbet 로그인ce 2006. Furthermore ABX is develop1xbet 로그인g a PET diagnostic for prostate cancer,¹⁸F-PSMA-1007, which received market1xbet 로그인g authorization 1xbet 로그인 France 1xbet 로그인 December 2021.